Finding Barriers and Designing Solutions to Promote Women s Cancer Screening in South Africa (FIND)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05414097|
Recruitment Status : Recruiting
First Posted : June 10, 2022
Last Update Posted : August 11, 2022
|Condition or disease||Intervention/treatment|
|Cervical Cancer||Other: Semi-structured focus group discussions Women Other: semi-structured focus groups discussion- Men Other: In-depth key stakeholders interviews Other: Discrete Choice Women Experiment Other: Development and User Pre-testing Workshops|
Cervical cancer is a leading cause of cancer death among South African women. Despite a comprehensive national cancer control policy, cervical screening coverage is low and attrition during on-ward referrals for diagnostic confirmation and treatment remains common.
This study uses a sequential mixed-methods design:
Phase 1) A qualitative exploratory phase using focus groups and in-depth interviews with women, men, other stakeholders will inform our design and interpretation of quantitative findings from a multi-cohort DCE.
Phase 2)Women will be recruited to participate in the DCE and determine their preferences for cancer screening services.
Phase 3) Design Thinking to co-create an intervention package for cervical cancer screening and enhanced linkage between screening, diagnosis, and treatment will be created.
|Study Type :||Observational|
|Estimated Enrollment :||388 participants|
|Official Title:||Finding Barriers and Designing Solutions to Promote Women s Cancer Screening in South Africa|
|Actual Study Start Date :||July 16, 2022|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||July 2025|
Phase 1 : 24 Women
HIV-positive, previously screened forcervical cancer , HIV-positive, not previously screened for cervical cancer, HIV-negative, previously screened for cervical cancer, HIV-negative, not previously screened for cervical cancer
Other: Semi-structured focus group discussions Women
Semi-structured focus group discussions to explore women's experiences with cervical cancer screening and treatment.
Phase 1: 16 Men
Male partners in 4 focus groups, referred by women previously screened or treated for cervical cancer and referred by women not previously screened for cervical cancer
Other: semi-structured focus groups discussion- Men
Semi-structured focus group discussions to explore partner dynamics related to women's ability to access cancer screening
Phase 1: 12 Key stakeholders
Women's groups, Women's health providers, laboratory personnel, NGOs and public health organization
Other: In-depth key stakeholders interviews
In-depth interviews to contextualise findings from women and men focus group discussions.
Phase 2:300 women
Women 18 years of age and older will be eligible for participation
Other: Discrete Choice Women Experiment
Discrete Choice Experiment to determine preferences to different cancer screening models.
Phase 3: 36 Women, women's health providers, and policy makers.
Adults 18 years and older will be eligible for participation. Up to 12 women previously screened for the study, up to 12 women's health providers and up to 12 policy makers
Other: Development and User Pre-testing Workshops
Development and User Pre-testing Workshops to explore acceptability and feasibility of proposed interventions designed using findings from Phases 1 &2.
- Phase 1: Barriers to cancer screening and engagement [ Time Frame: 6 months ]Barriers and enablers will be explored through focus groups and in-depth interviews with women, men and other stakeholders.
- Phase 2: Woman preferences for cancer screening services [ Time Frame: 1 year ]Preferences for cancer screening will be determined through the relative importance of the attribute according on how it is scored in the Discrete Choice Experiment.
- Phase 3: Acceptability and feasibility of multi-level package of interventions addressing barriers to cancer screening. [ Time Frame: 6 months ]Acceptability and feasibility will be measured through development and user pre-testing workshops.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05414097
|Contact: Cheryl Hendrickson||(919) firstname.lastname@example.org|
|Clinical HIV Research Unit Temba Lethu Wing Helen Joseph Hospital||Recruiting|
|Westdene, Johannesburg, South Africa, 2092|
|Contact: Tafadzwa Pasipamire email@example.com|
|Principal Investigator: Carla Chibwesha, MD, MSc|
|Principal Investigator:||Carla Chibwesha, MD, MSc||Department of Obstetrics and Gynecology University of North Carolina at Chapel Hill|